On the financial front, the micro-cap pharma stock has scripted a sharp turnaround, swinging from losses in financial year 2023-24 (FY24) to a profit in FY25, supported by a growth in its revenue.

The Central Electricity Regulatory Commission (CERC) has approved the implementation of market coupling in the Day-Ahead ...